Proprietary AI analyst is now available

Accrelist Valuation Multiples

Discover Accrelist's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Ecomiam, Bergholm, Labo Euromedis, DM-KER and more.

Accrelist Overview

About Accrelist

Accrelist Ltd is focused on the distribution of electronics components, plastic injection molding, mold design, and fabrication services. The company's segment comprises a Mechanical business unit (MBU), Aesthetic Medical Services (AMS), and others. Accrelist is focused on maintaining a diversified customer mix and product portfolio for MBU and EBU while continuing to expand upon the medical aesthetic products and services provided to consumers. it generates a vast majority of revenue from the MBU segment.


Founded

1986

HQ

Singapore

Employees

671

Financials (FY)

Revenue: $12M
EBITDA: $1M

EV

$16M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Accrelist Financials

Accrelist reported last fiscal year revenue of $12M and EBITDA of $1M.

In the same fiscal year, Accrelist generated $6M in gross profit, $1M in EBITDA, and had net loss of ($204K).


Accrelist P&L

In the most recent fiscal year, Accrelist reported revenue of $12M and EBITDA of $1M.

Accrelist is unprofitable as of last fiscal year, with gross margin of 47%, EBITDA margin of 8%, and net margin of (2%).

See analyst estimates for Accrelist
Last FY202320242025202620272028
Revenue$12M$17M$11M$12M
Gross Profit$6M$4M$4M$5M
Gross Margin47%25%36%45%
EBITDA$1M($1M)($3M)($176K)
EBITDA Margin8%(8%)(30%)(1%)
EBIT Margin(17%)(25%)(38%)(22%)
Net Profit($204K)($2M)($3M)($1M)
Net Margin(2%)(14%)(28%)(9%)

Financial data powered by Morningstar, Inc.

Accrelist Stock Performance

Accrelist has current market cap of $15M, and enterprise value of $16M.

Market Cap Evolution


Accrelist's stock price is $0.05.

Accrelist share price increased by 9.4% in the last 30 days.

See more trading valuation data for Accrelist
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$16M$15M-0.1%9.4%--$-0.00

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Accrelist Valuation Multiples

Accrelist trades at 1.3x EV/Revenue multiple, and 15.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Accrelist

Accrelist Financial Valuation Multiples

As of June 24, 2026, Accrelist has market cap of $15M and EV of $16M.

Accrelist has a P/E ratio of (74.2x).

Last FY202320242025202620272028
EV/Revenue1.3x0.9x1.4x1.3x
EV/EBITDA15.5x(12.1x)(4.7x)(89.6x)
EV/EBIT(7.7x)(3.7x)(3.6x)(6.0x)
EV/Gross Profit2.8x3.8x3.8x3.0x
P/E(74.2x)(6.3x)(4.8x)(14.4x)
EV/FCF66.4x(2.8x)(4.2x)(35.6x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Accrelist Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Accrelist Margins & Growth Rates

In the most recent fiscal year, Accrelist reported gross margin of 47%, EBITDA margin of 8%, and net margin of (2%).

See estimated margins and future growth rates for Accrelist

Accrelist Margins

Last FY202420252026202720282029
Gross Margin47%36%45%47%
EBITDA Margin8%(30%)(1%)8%
EBIT Margin(17%)(38%)(22%)(17%)
Net Margin(2%)(28%)(9%)(2%)
FCF Margin2%(33%)(4%)2%

Accrelist Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth(32%)4%3%
Gross Profit Growth(1%)28%7%
EBITDA Growth157%(95%)(677%)
EBIT Growth2%(39%)(22%)
Net Profit Growth32%(67%)(81%)
FCF Growth(33%)(88%)(154%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Accrelist Operational KPIs

Accrelist's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.0M for the same period.

Accrelist's Rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Accrelist's Rule of X is 15% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Accrelist
Last FY202320242025202620272028
Rule of 4011%---
Bessemer Rule of X15%---
Revenue per Employee$0.0M---
Opex per Employee$0.0M---
S&M Expenses to Revenue4%5%8%6%
G&A Expenses to Revenue60%45%67%62%
Opex to Revenue64%50%74%67%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Accrelist Competitors

Accrelist competitors include Ecomiam, Bergholm, Labo Euromedis, DM-KER, KDA Group, Innelec Multimedia, Fountain, Longino & Cardenal, Sipex and High Quality Food.

Most Accrelist public comparables operate across Wholesale Distribution.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Ecomiam0.3x0.3x(5.2x)(8.9x)
Bergholm0.2x-5.1x-
Labo Euromedis0.2x-9.6x-
DM-KER1.5x-10.8x-
KDA Group92.1x-(2.6x)-
Innelec Multimedia0.2x0.2x(27.9x)18.3x
Fountain0.4x-4.1x-
Longino & Cardenal0.3x0.3x14.0x7.8x

This data is available for Pro users. Sign up to see all Accrelist competitors and their valuation data.

Start Free Trial

Acquisitions by Accrelist

Accrelist has acquired 1 company to date.

Last acquisition by Accrelist was on April 18th 2023. Accrelist acquired SJY Medical for $800K (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Accrelist

SJY Medical
Description
-
HQ CountrySingapore
HQ City
Singapore
Deal Date18 Apr 2023
Valuation$800K
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Accrelist acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Accrelist

When was Accrelist founded?Accrelist was founded in 1986.
Where is Accrelist headquartered?Accrelist is headquartered in Singapore.
How many employees does Accrelist have?As of today, Accrelist has over 671 employees.
Is Accrelist publicly listed?Yes, Accrelist is a public company listed on Singapore Exchange.
What is the stock symbol of Accrelist?Accrelist trades under QZG ticker.
When did Accrelist go public?Accrelist went public in 2002.
Who are competitors of Accrelist?Accrelist main competitors include Ecomiam, Bergholm, Labo Euromedis, DM-KER, KDA Group, Innelec Multimedia, Fountain, Longino & Cardenal, Sipex, High Quality Food.
What is the current market cap of Accrelist?Accrelist's current market cap is $15M.
What is the current revenue of Accrelist?Accrelist's last fiscal year revenue is $12M.
What is the current EV/Revenue multiple of Accrelist?Current revenue multiple of Accrelist is 1.3x.
Is Accrelist profitable?No, Accrelist is not profitable.
How many companies Accrelist has acquired to date?As of June 2026, Accrelist has acquired 1 company.
What was the largest acquisition by Accrelist?$800K acquisition of SJY Medical on 18th April 2023 was the largest M&A Accrelist has done to date.
What companies Accrelist acquired?Accrelist acquired SJY Medical.
In how many companies Accrelist has invested to date?Accrelist hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Accrelist

Lists including Accrelist

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial